spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Factor IX 

 HSMN NewsFeed - 29 Apr 2024
Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B
Biopharmaceuticals Diagnostics FDA
 HSMN NewsFeed - 22 Nov 2022
U.S. Food and Drug Administration Approves CSL's Hemgenix(R) eEtranacogene dezaparvovec-drlb), the First Gene Therapy for Hemophilia B
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Jul 2020
IDELVION(R) Becomes First and Only Factor IX Therapy with 21-Day Prophylactic Dosing
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Apr 2020
HEMA Biologics(TM) Announces FDA Approval of SEVENFACT(R) [coagulation factor VIIa (recombinant)-jncw] for Treatment and Control of Bleeding Episodes Occurring in Adult and Adolescent Hemophilia A and B Patients with Inhibitors
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Aug 2018
IDELVION(R) 3500 IU Vials Now Available to Provide Convenience to Patients
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 8 Feb 2018
Novo Nordisk Launches Rebinyn(R) in the United States for People with Hemophilia B
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 25 Oct 2017
Sobi: Alprolix(R) Approved in the Kingdom of Saudi Arabia for the Treatment of Haemophilia B
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 13 May 2016
Alprolix(R) (rFIXFc) approved in the EU for the treatment of haemophilia B
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Dec 2015
Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-FIX, First In Vivo Protein Replacement Platform Program For Treatment Of Hemophilia B
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Oct 2014
Regado Biosciences Appoints Michael A. Metzger CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Aug 2014
Health Canada Approves Eloctate(TM), the First Therapy to Extend the Interval Between Prophylactic Infusions in Hemophilia A
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 16 Jul 2014
Pfizer Announces Positive Top-Line Results From Phase 3 Study Of NONACOG ALFA (BeneFIX(R)) Once-Weekly Prophylaxis For Hemophilia B
Biopharmaceuticals
 HSMN NewsFeed - 24 Mar 2014
Health Canada Approves Biogen Idec's Long-Acting ALPROLIX(TM) Therapy for Hemophilia B
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Dec 2013
Baxter Receives FDA Approval of FEIBA [Anti-Inhibitor Coagulant Complex] for Prophylactic Treatment of Hemophilia A&B Patients with Inhibitors
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Dec 2013
Regado Biosciences Strengthens Executive Leadership
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Dec 2012
Regado Biosciences, Inc. Secures $51 Million Series E Financing
Biopharmaceuticals Cardiology Venture Capital
 HSMN NewsFeed - 28 Nov 2012
Bayer Announces Recruitment Achievement for Investigational Hemophilia Treatment
Biopharmaceuticals
 HSMN NewsFeed - 20 Nov 2012
Ipsen and Inspiration Biopharmaceuticals Announce That OBI-1 Has Received Fast Track Designation from FDA for Acquired Hemophilia A
Biopharmaceuticals
 HSMN NewsFeed - 31 Oct 2012
Inspiration Biopharmaceuticals Files for Chapter 11 Protection in Order to Pursue a Broad Strategic Transaction
Biopharmaceuticals
 HSMN NewsFeed - 18 Sep 2012
Biopharmaceutical Industry Veterans Join Inspiration Biopharmaceuticals Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Aug 2012
Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
Biopharmaceuticals Licensing
 HSMN NewsFeed - 2 Aug 2012
Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Apr 2012
Ipsen Pursues Its Development in the United States with the Opening of Its New Commercial Headquarters in New Jersey (NJ)
Biopharmaceuticals
 HSMN NewsFeed - 17 Apr 2012
Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
Biopharmaceuticals
 HSMN NewsFeed - 4 Jan 2012
Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Nov 2011
Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Oct 2011
Inspiration Biopharmaceuticals Names John P. Butler Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Dec 2010
Swedish Orphan Biovitrum's Long-Lasting Hemophilia A Therapy Receives Orphan Drug Designation in the US
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Jul 2010
Phage Pharmaceuticals Appoints David Jackson as Vice President, Operations Planning
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 May 2010
Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 17 Dec 2009
Regado Biosciences, Inc. Completes $40 Million Series D Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 30 Jun 2009
Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products
Biopharmaceuticals
 HSMN NewsFeed - 11 Mar 2009
European Commission Approves ReFacto AF(TM) as a Variation to the Refacto(R) Marketing Authorisation
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Nov 2008
Biovitrum's and Syntonix's Novel Factor IXFc for Hemophilia B has Received Orphan Drug Designation From the FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Oct 2008
FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Jul 2008
Bayer HealthCare and Maxygen Announce Hematology Agreement
Biopharmaceuticals Licensing Acquisitions
 HSMN NewsFeed - 13 May 2008
FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Jan 2008
LFB Biotechnologies to Collaborate with GTC Biotherapeutics on Coagulation Factor IX Program
Biopharmaceuticals
 HSMN NewsFeed - 7 Jan 2008
Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
Biopharmaceuticals
 HSMN NewsFeed - 19 Nov 2007
Cook Pharmica Signs Agreement with Inspiration Biopharmaceuticals for the Transfer of its Clinical Manufacturing Process for Lead Hemophilia Compound
Biopharmaceuticals
 HSMN NewsFeed - 3 Jul 2007
Wyeth Begins Marketing and Distributing BeneFIX in Europe
Biopharmaceuticals Distribution
 HSMN NewsFeed - 1 Jun 2007
Semafore Pharmaceuticals Appoints Dr. Ullrich Schwertschlag Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Mar 2007
Wyeth Receives FDA Approval for New BeneFIX Features That Provide Hemophilia B Patients a Simpler and More Convenient Preparation Process for Recombinant Factor IX
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Mar 2007
Pain Therapeutics Licenses Biotechnology To Treat Rare Disorder
Biopharmaceuticals Licensing
 HSMN NewsFeed - 5 Feb 2007
Wyeth Pharmaceuticals and MediVas Announce Research Partnership to Develop Advanced Hemophilia Therapies
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 5 Feb 2007
Wyeth Pharmaceuticals and Nautilus Biotech Announce Collaboration to Develop Hemophilia Therapies
Biopharmaceuticals Licensing
 HSMN NewsFeed - 4 Jan 2007
Biogen Idec to Acquire Syntonix
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 2 Jan 2007
Hospitals, Healthcare Providers to Save with Premier Plasma Distribution Agreement with FFF Enterprises
Biopharmaceuticals Group Purchasing
 HSMN NewsFeed - 17 Oct 2006
NovoSeven(R) Becomes First and Only Recombinant Therapy for Treatment of Rare, Life-Threatening Bleeding Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Jul 2006
Bayer HealthCare Introduces Free Product Trial Program For Kogenate(R) FS with BIO-SET(R)
Biopharmaceuticals
 HSMN NewsFeed - 18 May 2006
Baxter and Jerini Advance Program to Develop Non-Intravenous Hemophilia Therapy
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 21

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 21 additional stories matching:
Factor IX
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.